News | Computed Tomography (CT) | April 27, 2022

Choice of oral contrast agent and adequacy of preparation impact detection of intra-abdominal nonsolid malignant deposits on CT, although NPV remains suboptimal

66-Year-Old Man With Locally Advanced Pancreatic Cancer Undergoing Chemotherapy

66-Year-Old Man With Locally Advanced Pancreatic Cancer Undergoing Chemotherapy: (A) Axial image from contrast-enhanced CT using positive oral contrast material, performed to monitor treatment response. Examination clinically interpreted as not showing metastatic disease. Unblinded retrospective image review shows tiny omental nodule (arrow) near bowel loops. Adequacy of bowel filling with contrast material rated very good. Both blinded retrospective readers detected nodule. (B) Axial image from contrast-enhanced CT performed two months later shows slight increase in size of nodule (arrow) and several new nodules (arrowheads), confirming lesion as missed malignant deposit. Image courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)


April 27, 2022 — According to ARRS’ American Journal of Roentgenology (AJR), the selection of oral contrast agent and optimization of bowel preparation for oncologic computed tomography (CT) could help avoid potentially severe clinical consequences of missed malignant deposits.

“CT has suboptimal NPV for malignant deposits in intraabdominal nonsolid organs,” wrote corresponding author Benjamin M. Yeh of the University of California, San Francisco. “Compared to neutral material, positive oral contrast material improves detection, particularly with adequate bowel filling.”

Yeh and team’s retrospective study included 265 patients (133 men, 132 women; median age, 61 years) who underwent an abdominopelvic CT examination where the report did not suggest presence of malignant deposits and subsequent CT examination within 6 months where the report indicated at least one unequivocal malignant deposit. Examinations used positive (iohexol; n=100) or neutral (water; n=165) oral agents. While reviewing images to assess visibility of deposits, a board-certified abdominal radiologist also assessed adequacy of bowel filling with oral contrast material.

NPV of CT for detection of malignant deposits in intraabdominal nonsolid organs was 65.8% for examinations using positive oral contrast material with adequate bowel filling, 45.2% for positive oral contrast material with inadequate bowel filling (p=.07), and 35.2% for neutral oral contrast material regardless of adequacy of bowel filling (p=.002).

“Results may differ when studying other types of contrast material regimens,” the authors of this AJR article noted, including barium-based, hyperosmolar iodine, sugar-alcohol neutral, or experimental dark oral agents.

For more information: www.arrs.org


Related Content

News | Radiology Business

May 29, 2024 — Strategic Radiology added a third California member to the nation’s leading coalition of independent ...

Time May 29, 2024
arrow
News | Lung Imaging

May 24, 2024 — Smokers who have small abnormalities on their CT scans that grow over time have a greater likelihood of ...

Time May 24, 2024
arrow
News | Radiation Therapy

May 23, 2024 — RaySearch Laboratories AB and C-RAD announced a collaboration agreement, aiming at jointly developing ...

Time May 23, 2024
arrow
News | Radiology Business

May 22, 2024 — Medtronic has announced new preliminary data from the VERITAS clinical study using its ILLUMISITE ...

Time May 22, 2024
arrow
News | Artificial Intelligence

May 22, 2024 — Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, recently ...

Time May 22, 2024
arrow
News | Artificial Intelligence

May 21, 2024 — According to a newly-published study of nearly 5,000 screening mammograms interpreted by an FDA-approved ...

Time May 21, 2024
arrow
News | Oncology Information Management Systems (OIMS)

May 21, 2024 — RaySearch Laboratories AB announced that the oncology information system RayCare* 2024A has been ...

Time May 21, 2024
arrow
News | Proton Therapy

May 21, 2024 — IBA, a world leader in particle accelerator technology, announced that it has signed a contract with the ...

Time May 21, 2024
arrow
News | Point-of-Care Ultrasound (POCUS)

May 20, 2024 — Exo (pronounced “echo”), a medical imaging software and devices company, announced the release of Exo ...

Time May 20, 2024
arrow
News | Radiology Business

May 20, 2024 — Associated Medical Professionals of NY (A.M.P.) announced that internationally recognized radiation ...

Time May 20, 2024
arrow
Subscribe Now